Yoko Nagai

Yoko Nagai

Auto-generated profile, based on publicly available information

Yoko Nagai

Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in Xenobiotica
Verified
Journal Article
Closed access
YNYoko Nagai
Yoko Nagai
MOMasataka Oitate
Masataka Oitate
HSHideyuki Shiozawa
Hideyuki Shiozawa
OAOsamu Ando
Osamu Ando
1. Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8. Here, we examined the pharmacokinetic (PK) profiles of DS-8201a and DXd in cynomolgus monkeys, a cross-reactive species. 2. Following intravenous (iv) administration of DS-8201a, the linker was stable in plasma, and systemic DXd exposure was low. DXd was rapidly cleared following iv dosing. Biodistribution studies revealed that intact DS-8201a was present mostly in the blood without tissue-specific retention. The major pathway of excretion for DXd was the faecal route following iv administration of radiolabelled DS-8201a. The only detectable metabolite in the urine and faeces was unmetabolized DXd. DXd is a substrate of organic anion transporting polypeptides, P-gp, and breast cancer resistance protein. 3. In conclusion, the stable linker in circulation and the high clearance of DXd upon release resulted in the low systemic exposure to DXd. Furthermore, the minimal tissue-specific retention and rapid excretion of DXd into faeces as its unmetabolized form with potentially limited impact on drug−drug interaction as a victim, were also critical elements of the PK profile of DS-8201a.

22 January 2024 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
YNYoko Nagai
Yoko Nagai
MOMasataka Oitate
Masataka Oitate
TSTakahiro Shibayama
Takahiro Shibayama
HTHideo Takakusa
Hideo Takakusa
NWNobuaki Watanabe
Nobuaki Watanabe

30 November 2020 in Biochemistry
Verified
Journal Article
Closed access
XSXizheng Sun
Xizheng Sun
RTReika Tokunaga
Reika Tokunaga
YNYoko Nagai
Yoko Nagai
RMRyo Miyahara
Ryo Miyahara
AKAkihiro Kishimura
Akihiro Kishimura
Takeshi MoriTakeshi Mori
Takeshi Mori